PharmTheon Translating knowledge

PharmTheon is a drug discovery and development research center dedicated to bridging the gap between fundamental scientific research and new therapies for patients with unmet medical needs.

About us

PharmTheon is part of the IOCB Tech Group, connecting academic and biotech research with innovation, investment, and support for science.

What do we do

Drug Discovery and Development

We advance therapeutic discovery by integrating medicinal chemistry, computational and AI-driven drug design, high-throughput screening, and compound optimization with disease biology, assay development, biophysical and functional characterization, target engagement studies, biomarker identification, patient stratification, and in vivo proof-of-concept studies.

Read more

We establish co-development partnerships and provide small-molecule drug discovery services.

Medicinal Chemistry

We provide medicinal chemistry expertise, including hit identification, computational and AI-driven drug design, hit-to-lead development, structure–activity relationship (SAR) studies, and lead optimization to accelerate small-molecule drug discovery.

Biophysical & Structural Characterization

We investigate molecular interactions, target engagement, and binding mechanisms using biophysical assays and structural biology approaches, including X-ray crystallography, NMR, and cryo-EM.

Functional Assays & In Vivo Validation

We develop biochemical and cell-based assays to validate therapeutic targets, screen and characterize compounds, and evaluate their biological activity. We establish in vivo proof-of-concept studies to assess therapeutic potential.

Biomarkers & Patient Stratification

We identify disease-relevant biomarkers and define target patient populations to guide therapeutic development, inform assay design, and support translational strategies.

Collaboration Models & Partnerships

We offer flexible collaboration models, including co-development partnerships with shared investment, intellectual property and commercial upside, joint grant-funded programs, and fee-for-service drug discovery. We tailor each partnership to the scientific goals, funding opportunities, and needs of our collaborators.

Read more

We provide

Intellectual Property Assessment

We identify any patents or proprietary technologies that may interfere with or enhance specific aspects of the project.

Go/No-Go (GNG) decision points

We define and assess Go/No-Go (GNG) decision points, including the key data or milestones needed to determine whether the project should proceed, be modified, or be discontinued.

Assay Validation and Quality Assurance

We ensure that all assays used to assess target engagement, functional activity, and therapeutic outcomes are properly validated, reproducible, and meet high-quality standards.

Pharmtheon office

Advisory board

William Lee

Former Executive Vice President of Research at Gilead Sciences

James Lorens

Head of Oncology and a founding scientist at Rigel Pharmaceuticals Inc (RIGL)

Ursula Vogel

Executive Business & Corporate Development Advisor

Vít Perlík

Director of Regulatory Science and Clinical Development in Pharminvent

David Andrews

Ex-Senior Director, Oncology R&D, AstraZeneca

David Smith

Former Open Innovation Programme at AstraZeneca

PharmTheon Team

Katarína Pšenáková

Co-CEO

katarina.psenakova@pharmtheon.cz
+420 722 406 095

Štěpán Vyskočil

Chief Scientific Advisor

Daniel Glynn

Project manager

Václav Veverka

Scientific Advisor

Petra Maternová

Office manager

office@pharmtheon.cz
+420 602 505 835

Kateřina Tsolov

CFO

Petra Břehová

Head of laboratory

Medicinal Chemistry

Petr Špaček

Automation scientist

Medicinal Chemistry

Ondřej Štěpánek

Senior scientist

Medicinal Chemistry

Peter Urbanovský

Senior scientist

Medicinal Chemistry

Mbilo Misehe

Senior scientist

Medicinal Chemistry

Martin Pošta

Senior scientist

Medicinal Chemistry

Michal Rahm

Junior scientist

Medicinal Chemistry

Marijo Čičak

Junior scientist

Medicinal Chemistry

Matúš Drexler

Data & Automation scientist

Biochemistry

Michal Svoboda

Senior scientist

Biochemistry

Ilona Kalasová

Senior scientist

Cell Biology

Monika Nedomová

Senior scientist

Cell Biology

Veronika Biddle

Senior scientist

Cell Biology

Ondřej Martinec

Senior scientist

Cell Biology

Oksana Tsyklauri

Senior scientist

In Vivo Biology

Pavla Duspiva

Junior scientist

In Vivo Biology

Valeriia Kopytko

Research assistant / Lab manager

Biochemistry

Marion Wendenbaum

Research assistant

Cell Biology

Contact us

Českomoravská 2532/19b
190 00 Praha 9

+420 602 505 835
office@pharmtheon.cz

IOCB TECH Group

IOCB Tech group transforms cutting-edge scientific discoveries emerging from basic research at the Institute of Organic Chemistry and Biochemistry (IOCB), into real-world solutions by supporting the development of innovative research, fostering biotech entrepreneurship, and bridging the gap between the lab and market. Through commercialization, incubation, and public engagement, we help science grow into impactful technologies that benefit society.

Our activities – Bridging Science & Business

News

See all

Oznámení o rozdělení společnosti IOCB TECH s.r.o. vyčleněním sloučením se společností PharmTheon s.r.o.

Společnost PharmTheon s.r.o. zveřejňuje upozornění pro věřitele, zástupce zaměstnanců, zaměstnance a společníky na jejich práva v souvislosti s plánovaným rozdělením společnosti IOCB TECH s.r.o. formou vyčlenění sloučením se společností PharmTheon s.r.o.

19/11/2026

#bioequity #pharmtheon #translationalresearch #innovation #czechscience | PharmTheon

Big day for PharmTheon at #BioEquity. We talked about how to bring great science to market - and came to a very Czech conclusion: be brutally honest, don’t fear failure, and keep going. The good news? The great science has always been here. The even better news? We’re building an ecosystem that makes it investable. #PharmTheon #TranslationalResearch #Innovation #CzechScience

18/5/2026

🧬 A Day in the Life of a Translational Research Center 🧬 | PharmTheon

🧬 A Day in the Life of a Translational Research Center 🧬   At PharmTheon, no two days are ever the same, but they all share one thing - a drive to turn great science into real-world solutions. We’re a team of 18 scientists - 9 chemists and 9 biologists, working side by side in three bold projects: 1. Overcoming treatment limitations to enhance conventional therapies 2. Advancing innovative molecules to support next-generation immunotherapies 3. Designing optimized molecules for sharper and faster diagnostics What does that look like in real life? Scroll through the stunning behind-the-scenes photos by Jana Plavec, Czech Academy of Sciences.   #PharmTheon #IOCBTech #TranslationalResearch #DrugDiscovery #Biotech #Innovation #AppliedResearch #ScienceToImpact #CzechScience

21/8/2025